Skip to main content

14 - References

References

Pharmacokinetics CHAPTER 11 References

  1. Jakobsen MI, et  al. The significance of sampling time in therapeutic drug monitoring of clozapine. Acta Psychiatr Scand 2017; 135:159–169.
  2. Hiemke C. Concentration-­effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 2019; 41:174–179.
  3. Hart XM, et al. Update lessons from positron emission tomography imaging Part I: a systematic critical review on therapeutic plasma concentrations of antipsychotics. Ther Drug Monit 2024; 46:16–32.
  4. Kapur S, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-­blind PET study of first-­episode schizophrenia. Am J Psychiatry 2000; 157:514–520.
  5. Kronig MH, et al. Plasma clozapine levels and clinical response for treatment-­refractory schizophrenic patients. Am J Psychiatry 1995; 152:179–182.
  6. Taylor D, et al. Doses of carbamazepine and valproate in bipolar affective disorder. Psychiatric Bulletin 1997; 21:221–223.
  7. Eadie MJ. Anticonvulsant drugs. Drugs 1984; 27:328–363.
  8. Chbili C, et al. Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease. Ann Biol Clin (Paris) 2014; 72:453–459.
  9. Cohen AF, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42:535–541.
  10. Kilpatrick ES, et  al. Concentration-­effect and concentration-­toxicity relations with lamotrigine: a prospective study. Epilepsia 1996; 37:534–538.
  11. Johannessen SI, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25:347–363.
  12. Kagawa S, et al. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-­resistant depressive disorder. Ther Drug Monit 2014; 36:730–733.
  13. Nakamura A, et al. Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-­resistant depressive disorder from plasma lamotrigine concentration at week 2. Ther Drug Monit 2016; 38:379–382.
  14. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997; 54:9–13.
  15. Anon. Using lithium safely. Drug Ther Bull 1999; 37:22–24.
  16. Nicholson J, et al. Monitoring patients on lithium – a good practice guideline. Psychiatric Bulletin 2002; 26:348–351.
  17. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]. 2014 (last updated December 2023, last accessed August 2024); https://www.nice.org.uk/guidance/cg185.
  18. Severus WE, et al. What is the optimal serum lithium level in the long-­term treatment of bipolar disorder – a review? Bipolar Disord 2008; 10:231–237.
  19. Nolen WA, et al. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-­blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord 2013; 15:100–109.
  20. Nazirizadeh Y, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 2010; 66:797–803.
  21. Schoretsanitis G, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol 2018; 11:625–639.
  22. Taylor D, et al. Plasma levels of tricyclics and related antidepressants: are they necessary or useful? Psychiatric Bulletin 1995; 19:548–550.
  23. Perucca E. Pharmacological and therapeutic properties of valproate. CNS Drugs 2002; 16:695–714.
  24. Allen MH, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163:272–275.
  25. Bowden CL, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153:765–770.
  26. Vazquez M, et al. Hyperammonemia associated with valproic acid concentrations. Biomed Res Int 2014; 2014:217269.
  27. Muller MJ, et al. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol 2008; 23:278–286.
  28. Muller MJ, et al. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry 2006; 39:41–46.
  29. Bergemann N, et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2004; 14:245–250.
  30. Muller MJ, et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 2007; 41:673–679.
  31. Sparshatt A, et al. Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 2009; 120:416–428.
  32. Schoretsanitis G, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry 2018; 19:162–174.
  33. Jönsson AK, et al. A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit 2019; 41:348–356.
  34. Reeves S, et  al. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer’s disease. Brain 2017; 140:1117–1127.
  35. Reeves S, et  al. Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-­onset schizophrenia-­like psychosis (VLOSLP). Int J Geriatr Psychiatry 2018; 33:396–404.
  36. Bowskill SV, et al. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002–2010. Hum Psychopharmacol 2012; 27:507–513.
  37. Mace S, et al. Aripiprazole: dose-­response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2008; 23:773–780.

876 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 11 38. Sparshatt A, et al. A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010; 71:1447–1456. 39. Kirschbaum KM, et al. Therapeutic monitoring of aripiprazole by HPLC with column-­switching and spectrophotometric detection. Clin Chem 2005; 51:1718–1721. 40. Kirschbaum KM, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008; 9:212–218. 41. Molden E, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28:744–749. 42. Bachmann CJ, et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 2008; 30:462–466. 43. Hendset M, et al. Impact of the CYP2D6 genotype on steady-­state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63:1147–1151. 44. Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-­monthly in adult schizophrenia: an open-­label, parallel-­ arm, multiple-­dose study. Schizophr Res 2013; 150:281–288. 45. Korell J, et al. Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine. Eur J Clin Pharmacol 2018; 74:593–599. 46. Harlin M, et al. Aripiprazole plasma concentrations delivered from two 2-­month long-­acting injectable formulations: an indirect comparison. Neuropsychiatr Dis Treat 2023; 19:1409–1416. 47. Haring C, et al. Influence of patient-­related variables on clozapine plasma levels. Am J Psychiatry 1990; 147:1471–1475. 48. Haring C, et  al. Dose-­related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989; 99 Suppl:S38–S40. 49. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171:109–112. 50. Ng CH, et al. An inter-­ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005; 20:163–168. 51. Ruan CJ, et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol 2019; 39:135–144. 52. De Leon J, et al. Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview. Indian J Psychol Med 2020; 42:4–10. 53. Suhas S, et al. Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. Schizophr Res 2020; 222:195–201. 54. Bhattacharya R, et al. Clozapine prescribing: comparison of clozapine dosage and plasma levels between white British and Bangladeshi patients. BJPsych Bull 2021; 45:22–27. 55. Ruan CJ, et al. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13. J Clin Psychopharmacol 2019; 39:644–648. 56. De Leon J, et al. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia Pac Psychiatry 2020; 12:e12384. 57. Rostami-­Hodjegan A, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24:70–78. 58. Taylor D, et al. Predicting clozapine dose required to achieve a therapeutic plasma concentration – a comparison of a population algorithm and three algorithms based on gene variant models. J Psychopharmacol 2023; 37:1030–1039. 59. Haack MJ, et  al. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol 2003; 13:381–385. 60. De Leon J, et  al. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1059–1063. 61. Espnes KA, et al. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. Ther Drug Monit 2012; 34:489–492. 62. VanderZwaag C, et al. Response of patients with treatment-­refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153:1579–1584. 63. Perry PJ, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 1991; 148:231–235. 64. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991; 52:23–25. 65. Spina E, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000; 148:83–89. 66. Hasegawa M, et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13:383–390. 67. Potkin SG, et al. Plasma clozapine concentrations predict clinical response in treatment-­resistant schizophrenia. J Clin Psychiatry 1994; 55 Suppl B:133–136. 68. Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull 2001; 35:19–29. 69. Llorca PM, et al. Effectiveness of clozapine in neuroleptic-­resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci 2002; 27:30–37. 70. Xiang YQ, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 2006; 83:201–210.

Pharmacokinetics CHAPTER 11 71. Stieffenhofer V, et al. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Pharmacopsychiatry 2011; 44:55–59. 72. Lee J, et al. Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approach. J Clin Psychiatry 2016; 77:681–687. 73. Turrion MC, et al. Intra-­individual variation of clozapine and norclozapine plasma levels in clinical practice. Rev Psiquiatr Salud Ment 2020; 13:31–35. 74. Khan AY, et al. Examining concentration-­dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 2005; 11:289–301. 75. Varma S, et  al. Clozapine-­related EEG changes and seizures: dose and plasma-­level relationships. Ther Adv Psychopharmacol 2011; 1:47–66. 76. Greenwood-­Smith C, et al. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol 2003; 17:234–238. 77. Yusufi B, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007; 22:238–243. 78. Remington G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 2013; 225:505–518. 79. Bogers J, et al. Feasibility and effect of increasing clozapine plasma levels in long-­stay patients with treatment-­resistant schizophrenia. J Clin Psychopharmacol 2023; 43:97–105. 80. Northwood K, et al. Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-­analysis and receiver operating characteristic curve analysis. Br J Psychiatry 2023; 222:241–245. 81. Couchman L, et al. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit 2010; 32:438–447. 82. Wickramarachchi P, et al. Biological variation in clozapine and metabolite reporting during therapeutic drug monitoring. Clin Chim Acta 2022; 531:183–187. 83. Volpicelli SA, et al. Determination of clozapine, norclozapine, and clozapine-­N-­oxide in serum by liquid chromatography. Clin Chem 1993; 39:1656–1659. 84. Guitton C, et al. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol 1999; 39:721–728. 85. Palego L, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-­related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:473–480. 86. Wang CY, et al. The differential effects of steady-­state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 2004; 44:785–792. 87. Schoretsanitis G, et al. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol 2019; 12:603–621. 88. Bishara D, et al. Olanzapine: a systematic review and meta-­regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013; 33:329–335. 89. Aravagiri M, et al. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-­performance liquid chromatography with electrochemical detection. Ther Drug Monit 1997; 19:307–313. 90. Gex-­Fabry M, et al. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25:46–53. 91. Bergemann N, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-­medication in schizophrenic patients. Pharmacopsychiatry 2004; 37:63–68. 92. Perry PJ, et al. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997; 17:472–477. 93. Fellows L, et al. Investigation of target plasma concentration–effect relationships for olanzapine in schizophrenia. Ther Drug Monit 2003; 25:682–689. 94. Mauri MC, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005; 20:55–60. 95. Rao ML, et  al. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr 2001; 69:510–517. 96. Robertson MD, et al. Olanzapine concentrations in clinical serum and postmortem blood specimens – when does therapeutic become toxic? J Forensic Sci 2000; 45:418–421. 97. Bech P, et  al. Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states. Nord J Psychiatry 2006; 60:181–182. 98. Schoretsanitis G, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 2020; 81:19cs13169. 99. Noel C. A review of a recently published guidelines’ ‘strong recommendation’ for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine. Ment Health Clin 2019; 9:287–293. 100. Wesner K, et al. Therapeutic reference range for olanzapine in schizophrenia: systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy. J Clin Psychiatry 2023; 84:22r14626. 101. Perry PJ, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25:250–254. 102. Kelly DL, et  al. Plasma concentrations of high-­dose olanzapine in a double-­blind crossover study. Hum Psychopharmacol 2006; 21:393–398.

878 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 11 103. Patel MX, et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999–2009. J Clin Psychopharmacol 2011; 31:411–417. 104. Tsuboi T, et  al. Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study. Pharmacopsychiatry 2015; 48:286–291. 105. Sparshatt A, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 2011; 72:1108–1123. 106. Hasselstrom J, et  al. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 2004; 26:486–491. 107. Winter HR, et  al. Steady-­state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine ­metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008; 18:81–98. 108. Li KY, et al. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. Acta Pharmacol Sin 2004; 25:390–394. 109. McConville BJ, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-­label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61:252–260. 110. Castberg I, et al. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 2007; 68:1540–1545. 111. Aichhorn W, et  al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006; 21:81–85. 112. Mauri MC, et al. Two weeks’ quetiapine treatment for schizophrenia, drug-­induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007; 8:2207–2213. 113. Patteet L, et al. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 2012; 34:629–651. 114. Fisher DS, et al. Plasma concentrations of quetiapine, N-­desalkylquetiapine, o-­desalkylquetiapine, 7-­hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors. Ther Drug Monit 2012; 34:415–421. 115. Sparshatt A, et al. Quetiapine: dose-­response relationship in schizophrenia. CNS Drugs 2008; 22:49–68. 116. Olesen OV, et  al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998; 20:380–384. 117. Remington G, et al. A PET study evaluating dopamine D2 receptor occupancy for long-­acting injectable risperidone. Am J Psychiatry 2006; 163:396–401. 118. Seto K, et al. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit 2011; 33:275–283. 119. Lane HY, et  al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000; 61:209–214. 120. Taylor D. Risperidone long-­acting injection in practice – more questions than answers? Acta Psychiatr Scand 2006; 114:1–2. 121. Nyberg S, et al. Suggested minimal effective dose of risperidone based on PET-­measured D2 and 5-­HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869–875. 122. Uchida H, et al. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 2011; 31:318–325. 123. Pandina GJ, et al. A randomized, placebo-­controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010; 30:235–244. 124. Mauri MC, et al. Paliperidone long-­acting plasma level monitoring and a new method of evaluation of clinical stability. Pharmacopsychiatry 2017; 50:145–151. 125. Paletta S, et al. Two years of maintenance therapy with paliperidone long-­acting in schizophrenia and schizoaffective disorder: a study with plasma levels. Eur Neuropsychopharmacol 2016; 26:S556–S557. 126. Berwaerts J, et al. Efficacy and safety of the 3-­month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2015; 72:830–839. 127. Magnusson MO, et al. Dosing and switching strategies for paliperidone palmitate 3-­month formulation in patients with schizophrenia based on population pharmacokinetic modeling and simulation, and clinical trial data. CNS Drugs 2017; 31:273–288. 128. T’Jollyn H, et al. Model-­informed clinical development of once-­every-­6-­month injection of paliperidone palmitate in patients with schizophrenia: a pharmacometric bridging approach (Part I). Eur J Drug Metab Pharmacokinet 2024; 49:477–489. 129. Álamo C. Risperidone ISM as a new option in the clinical management of schizophrenia: a narrative review. Adv Ther 2022; 39:4875–4891. 130. Biso L, et al. Therapeutic drug monitoring in psychiatry: enhancing treatment precision and patient outcomes. Pharmaceuticals (Basel) 2024; 17:642.

No comments to display

Back to top